
Work Here?
Doximity is a digital platform for United States healthcare professionals, offering a professional social network, a residency navigator, and telehealth services. Users join to connect with peers, share medical insights, track residency applications, and conduct remote patient visits. Revenue comes from targeted advertising to medical professionals, premium subscriptions, and telehealth usage fees. Its goal is to improve communication and collaboration among clinicians, support career development and residency placement, and expand access to care through convenient telehealth.
Industries
Enterprise Software
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2010
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$687.8M
Above
Industry Average
Funded Over
4 Rounds
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Family Planning Benefits
Paid Vacation
Paid Holidays
Wellness Program
Dutch Bros, the US coffee chain, is attracting attention for its strong same-store sales performance and expansion strategy. The company has achieved average same-store sales growth of 6% over the past two years and expects revenue growth of 27.7% for the next year. Meanwhile, two cash-generating companies face challenges. Doximity, the physician networking platform, has seen costs rise faster than revenue, with operating margins declining by 10.5 percentage points. Its estimated sales growth of 4.6% for the next 12 months suggests slowing demand. Silgan Holdings, the packaging supplier, has experienced annual revenue growth of just 4.7% over five years and earnings per share growth of only 2.4% annually.
Doximity reported Q2 revenue of $156.6 million, up 7.3% year on year and beating analyst estimates of $151.3 million. The medical professional network's adjusted earnings per share of $0.29 missed expectations by 4.2%. The company attributed growth to increased adoption of AI-powered clinical tools. CEO Jeffrey Tangney noted quarterly active workflow prescribers grew more than 30% year on year, with nearly half using AI tools. Operating margin declined to 21.5% from 37.4% in the prior year period. The company raised full-year revenue guidance to $676 million from $670 million but set EBITDA guidance below analyst estimates at $319 million. CFO Matthew Sonefeldt said higher AI usage prompted increased investment to capture long-term opportunities, explaining near-term margin pressure.
Wells Fargo downgraded Doximity to Underweight from Equal Weight with an $18 price target, days after the medical professionals' digital platform surged 32.58% on earnings. Analyst Stan Berenshteyn noted that whilst Doximity's outlook remains unchanged, the stock now trades near faster-growing peers at approximately 32 times earnings despite roughly 11% revenue growth over the past year. The analyst argued remaining upside depends on an AI narrative that is difficult to quantify in estimates. Survey work suggests wallet-share gains with top accounts are largely complete. The $18 target sits at the bottom of analyst estimates ranging to $47. Wells Fargo cited unfavourable risk-reward until Doximity's AI strategy produces clearer growth acceleration.
Doximity reported fiscal first-quarter 2027 results with revenue rising to $156.62 million from $145.91 million year-over-year, though net income and earnings per share declined. The company raised its guidance to $170–171 million for second-quarter revenue and $671–681 million for the full year, citing rapid uptake of its clinical AI tools. The healthcare network is monetising physician engagement through software and marketing revenue, now enhanced by clinical AI capabilities. Key near-term catalysts include how quickly AI tools convert to contracted revenue and whether health systems expand adoption. Despite the stock's 31% rise, fair value estimates from the Simply Wall St Community range from roughly $18 to under $36.72, reflecting varied views on Doximity's AI opportunity. Main risks include execution challenges, management changes, and potential slowdowns in pharmaceutical spending.
This digital healthcare stock spikes 100% after cracking The AI code. Read Time: 4 mins AI Generated Image Shares of Doximity Inc. surged in premarket trading on Friday after the digital medical platform's management revealed strong economics for its new AI-powered search product, with the stock gaining more than 130% at one point before paring some of those gains after the US market opened. The rally followed comments from CEO Jeffrey Tangney, who said Doximity is generating more than 10 times the revenue per AI search than the cost of running it. The comments have fuelled expectations that the company's AI investments could open a significantly larger market while supporting stronger long-term margins. "It's early days on our AI search product, but I can tell you we're earning more than 10 times per search in revenue than it costs," Tangney said during Doximity's first-quarter fiscal 2027 earnings call on Thursday, as per CNBC. He added that AI costs could decline further as models become more efficient, potentially improving the economics of the product over time. Doximity Raises Revenue Outlook The AI opportunity comes on top of an already strong quarterly performance. Doximity reported first-quarter revenue of $156.6 million and adjusted EBITDA of $74.8 million, with both figures exceeding consensus estimates. The company also raised its full-year fiscal 2027 revenue guidance by $6 million, or about 5%, to a range of $671 million-$681 million. However, analysts believe the upgraded guidance may not fully reflect the potential contribution from Doximity's expanding AI business. Piper Sandler analyst Jessica Tassan said the fiscal 2027 guidance increase was largely driven by the first-quarter beat and did not include a significant contribution from the growing AI commercial pipeline discussed by management, CNBC reports. She described the company's approach to forecasting AI search revenue as conservative. That leaves room for the AI product to become an additional growth driver if adoption accelerates. AI Search Could Expand Doximity's Market Tangney also indicated that the impact of AI search could extend beyond improving the economics of Doximity's existing business. The CEO said the technology had unexpectedly expanded the company's total addressable market (TAM) across the healthcare and pharmaceutical sectors. That potential has attracted attention from analysts. Michael Cherney of Leerink Partners said the AI search product is strengthening confidence that Doximity's increased investment in artificial intelligence could ultimately support attractive long-term margins. The economics are particularly notable because AI products typically require significant computing resources. If Doximity can generate substantially more revenue from each search than the cost of operating it, rising usage could potentially translate into meaningful incremental profitability. Tangney also expects the cost side of the equation to improve as AI models become more efficient. Short Sellers Add Fuel To Doximity Rally The sharp move in Doximity shares may also have been amplified by positioning in the stock. Around 17% of Doximity's freely tradable shares were sold short heading into the earnings announcement, according to FactSet. The stronger-than-expected financial results and bullish comments around AI could have forced some short sellers to buy back shares to close their positions. Such buying can accelerate a stock's rise, creating what is commonly known as a short squeeze. Doximity had entered Friday's session under considerable pressure. The stock was down around 50% for the year before the latest earnings report, with the company valued at about $3.7 billion before the surge. The combination of heavy short interest, strong quarterly numbers and the unexpectedly high profitability of its AI search product therefore created a powerful catalyst for the stock. Doximity Stock Performance Doximity shares rose more than 130% in premarket trading at their peak on Friday before giving up part of the gain after the regular session began. The stock was last reported up around 55% in the supplied market update. As of 7 August 2026, 12:06 p.m. GMT-4, Doximity was trading at $27.79, up 34.51%, or $7.13, from the previous close of $20.66. The stock opened at $38.86 and touched an intraday high of $40, before falling to an intraday low of $27.75. Its 52-week range stood at $17.15-$76.51. Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories - On NDTV Profit.
Find jobs on Simplify and start your career today
Industries
Enterprise Software
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2010
Find jobs on Simplify and start your career today